BAD and prostate carcinoma: Agshin et al. [19] also found that prostatic carcinoma cell line LNCaP, which was resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, became sensitive to TRAIL and promote apoptotic rate after overexpression of full-length, wild-type BAD.